ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

acoramidis

Also written as “Acoramidis”, “Acoramidis (AG10)” and “AG10”.

Its studies are mostly in Amyloid Neuropathies, Familial · Amyloidosis, Hereditary, Transthyretin-Related · Amyloidosis, led by 3 companies.

Drug pageAcoramidis: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jul 6, 202615 company-led studies, 6 open or runningNext primary completion: Sep 17, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BridgeBio114 open or runningphase 4since Jul 6, 2026Sep 18, 2017Apr 15, 2028phase 3 · NCT04988386
AstraZenecaits history only31 open or runningphase 4since Dec 15, 2025Nov 6, 2020Mar 31, 2028phase 4 · NCT07306949
Bayerits history only11 open or runningphase 4since Dec 11, 2025Dec 11, 2025Sep 17, 2027phase 4 · NCT07298044

Also a collaborator on its studies: Celerion.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of BridgeBio only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 18, 2017First study: phase 1 study in Amyloid Neuropathies, FamilialFirst studyNCT03294707 · 56 enrolled · United States
  2. Feb 7, 2018Phase 2 study in Familial ATTR-CM (ATTRm-CM, or FAC)NCT03458130 · 49 enrolled · United States
  3. May 11, 2018Phase 2 study in Amyloid Neuropathies, FamilialNCT03536767 · 47 enrolled · United States
  4. Feb 27, 2019Phase 3 study in AmyloidosisNCT03860935 · 632 enrolled · United States, Australia, Belgium and more
  5. Dec 9, 2019Named acoramidisINNProposed as its International Nonproprietary Name in WHO's List 122
  6. May 22, 2020Phase 3 study in Amyloid Neuropathies, FamilialNCT04418024 · United States
  7. Feb 19, 2021Phase 1 study in AmyloidosisNCT04769479 · 14 enrolled · United Kingdom
  8. Apr 29, 2021Phase 3 study in Amyloid Neuropathies, FamilialNCT04882735
  9. Jul 13, 2021Phase 3 study in Amyloid Neuropathies, FamilialNCT04988386 · 389 enrolled · United States, Australia, Belgium and more
  10. Aug 5, 2024Phase 3 study in AmyloidosisNCT06563895 · 587 planned · United States, Argentina, Australia and more
  11. Aug 7, 2025Phase 3 study in Amyloidosis, FamilialNCT07116473 · 250 planned
  12. Jul 6, 2026Phase 4 study in AmyloidosisNCT07695701 · 150 planned · United States
  13. Oct 14, 2026Phase 2 study terminatedStudy stoppedNCT03536767 · “Study ended by the sponsor due to meeting Study Objectives”

Ahead

  1. Apr 15, 2028Primary completion: phase 3 study in Amyloid Neuropathies, FamilialNCT04988386
  2. Aug 2030Primary completion: phase 4 study in AmyloidosisNCT07695701
  3. Oct 2031Primary completion: phase 3 study in AmyloidosisNCT06563895
  4. Nov 2037Primary completion: phase 3 study in Amyloidosis, FamilialNCT07116473

TargetBeta

TTR →read by rule
“Transthyretin stabiliser; Transthyretin stabiliser”ChEMBL 37, by rule

Other programs on TTR

ProgramCompanyFurthest phaseStudies
tafamidisrulePfizerphase 429
coramitugNovo Nordiskphase 33
coramitugNovo Nordiskphase 12

Studies

All 11 BridgeBio leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07695701Amyloidosis · United States4RecruitingAug 2030150
NCT07116473Amyloidosis, Familial3Not yet recruitingNov 2037250
NCT06563895Amyloidosis · United States, Argentina, Australia and more3RecruitingOct 2031587
NCT04988386Amyloid Neuropathies, Familial · United States, Australia, Belgium and more3Active, not recruitingApr 15, 2028389
NCT04882735Amyloid Neuropathies, Familial3WithdrawnSep 20260
NCT04769479Amyloidosis · United Kingdom1CompletedAug 4, 202114
NCT04418024Amyloid Neuropathies, Familial · United States3WithdrawnMar 31, 20240
NCT03860935Amyloidosis · United States, Australia, Belgium and more3CompletedMay 11, 2023632
NCT03536767Amyloid Neuropathies, Familial · United States2TerminatedSep 15, 202547
NCT03458130Familial ATTR-CM (ATTRm-CM, or FAC) · United States2CompletedOct 5, 201849
NCT03294707Amyloid Neuropathies, Familial · United States1CompletedFeb 5, 201856

How it is read

Names in the registry

  • “Acoramidis”, 6 entries
  • “Acoramidis (AG10)”, 2 entries
  • “AG10”, 2 entries
  • “acoramidis”, 2 entries
  • “Acoramidis (AG10) oral tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.